Notes
The study was partly funded by Actavis Specialty Pharmaceuticals Co.
Reference
Tsoi B, et al. Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management. ClinicoEconomics and Outcomes Research : 17 Apr 2015. Available from: URL: http://dx.doi.org/10.2147/CEOR.S78115
Rights and permissions
About this article
Cite this article
Ulipristal cost-saving option for symptomatic uterine fibroids. PharmacoEcon Outcomes News 727, 31 (2015). https://doi.org/10.1007/s40274-015-2115-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2115-9